NS Partners Ltd Boosts Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• NS Partners Ltd increased its holdings in Intuitive Surgical, Inc. by 1.7%, acquiring an additional 1,241 shares, bringing its total to 73,795 shares valued at approximately $36.55 million.
• Intuitive Surgical reported a strong quarterly performance, with earnings per share of $2.19, exceeding analyst expectations by 0.26.
• Institutional investors control about 83.64% of Intuitive Surgical's total stock, indicating significant institutional interest in the company.

NS Partners Ltd raised its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 73,795 shares of the medical equipment provider's stock after acquiring an additional 1,241 shares during the quarter. Intuitive Surgical makes up about 1.6% of NS Partners Ltd's investment portfolio, making the stock its 20th biggest position. NS Partners Ltd's holdings in Intuitive Surgical were worth $36,548,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Chilton Capital Management LLC increased its stake in Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 43 shares during the last quarter. Parvin Asset Management LLC bought a new stake in Intuitive Surgical during the fourth quarter worth approximately $26,000. Global Financial Private Client LLC increased its stake in Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 38 shares during the last quarter. Elite Financial Inc. bought a new stake in Intuitive Surgical during the first quarter worth approximately $26,000. Finally, LFA Lugano Financial Advisors SA bought a new stake in Intuitive Surgical during the first quarter worth approximately $30,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Trading Up 0.1%

Shares of ISRG stock traded up $0.27 during trading hours on Friday, reaching $470.08. 1,445,546 shares of the company's stock were exchanged, compared to its average volume of 2,319,941. The stock's 50 day moving average is $516.52 and its 200-day moving average is $528.79. The company has a market cap of $168.51 billion, a price-to-earnings ratio of 65.56, a P/E/G ratio of 4.93 and a beta of 1.59. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The firm had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. During the same period in the prior year, the firm earned $1.78 EPS. The firm's revenue was up 21.4% on a year-over-year basis. Equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Activity at Intuitive Surgical

In related news, SVP Mark Brosius sold 216 shares of the company's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the transaction, the senior vice president directly owned 907 shares of the company's stock, valued at $510,740.77. This represents a 19.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the transaction, the executive vice president directly owned 353 shares in the company, valued at approximately $173,845.44. The trade was a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,903 shares of company stock valued at $7,932,778 in the last ninety days. Company insiders own 0.70% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on ISRG. UBS Group boosted their target price on Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Barclays dropped their target price on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Citigroup restated a "buy" rating and set a $650.00 target price (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Piper Sandler restated an "overweight" rating and set a $595.00 target price (up previously from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Finally, Royal Bank Of Canada boosted their target price on Intuitive Surgical from $605.00 to $615.00 and gave the company an "outperform" rating in a research report on Wednesday, July 23rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $595.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.